Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cedars-Sinai Medical Center
With
Bristol-Myers Squibb
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically-confirmed localized prostate cancer
Predicted probability of recurrence \>/= 30% as defined by the updated Kattan nomogram
Pathologic material available for gene expression analysis including cancer present in 2 or more cores and availability of unstained slides or formalin-fixed paraffin embedded tissue blocks.
No prior prostate cancer therapy (including hormonal, chemotherapy, radiation or surgery)
Subjects must be considered as candidates for radical prostatectomy
EGOG status
Men of child-bearing potential are required to use an effective means of contraception
Active angina, including active stable and unstable angina
Acute deep venous thrombosis and/or pulmonary embolism in the past 6 months
Any prior hormonal therapy including the use of PC Spes or estrogen containing nutriceuticals
Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma.
Patients with malignancy diagnosed more than 5 years ago and are disease free for at least 5 years are not excluded.
Recent (within 4 weeks) surgery or incomplete healing from surgery
Known history of hypersensitivity reaction to a drug formulated in Cremophor EL
Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment
Active infection requiring antibiotic therapy, or serious intercurrent illness.
Any other major illness that in the investigators judgment will substantially increase the risk associated with the subject's participation in this study.
Unwillingness or inability to comply with procedures required in this protocol.
Clareo Health | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
